Skip to main content
. 2019 Sep 16;2019(9):CD013120. doi: 10.1002/14651858.CD013120.pub2

Yim 2017.

Methods Randomised clinical trial
Participants Country: South Korea
Number randomised: 261
Post‐randomisation dropouts: not stated
Revised sample size: 261
Average age: not stated
Females: not stated
Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or variceal bleeding): not stated
Alcohol‐related cirrhosis: not stated
Viral‐related cirrhosis: not stated
Autoimmune disease‐related cirrhosis (e.g. PSC, PBC, AIH): not stated
Other causes for cirrhosis: not stated
Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated
Follow‐up in months: 0.25
Years of recruitment: 2007‐2016
Exclusion criteria
  • Allergic to third‐generation cephalosporins or quinolones

  • Antibiotics within 2 weeks

  • Open abdominal surgery within 4 weeks

  • Evidence of secondary peritonitis, intra‐abdominal haemorrhage, pancreatitis, tuberculous peritonitis or peritoneal carcinomatosis

  • Hepatocellular carcinoma with portal vein thrombosis

  • Pregnant women

  • HIV positivity

Interventions Participants were randomly assigned to three groups.
 Group 1: ciprofloxacin (n = not stated)
 Further details: (route and duration not stated)
 Group 2: cefotaxime (n = not stated)
 Further details: (route and duration not stated)
Group 3: ceftriaxone (n = not stated)
Further details: (route and duration not stated)
Number of participants in each group not stated
Outcomes None of the outcomes of interest were reported.
Notes Attempts were made to contact the authors in December 2018; there were no replies.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: a prepublished protocol was not available but the authors do not report routinely measured clinical outcomes adequately.
Other bias Low risk Comment: no other bias was noted.

AIH: autoimmune hepatitis
 IV: intravenous
 PBC: primary biliary cholangitis
 PSC: primary sclerosing cholangitis
 SBP: spontaneous bacterial peritonitis